TAILIEUCHUNG - RISK MANAGEMENT FOR CENTRAL BANK FOREIGN RESERVES

It’s easy to forget how much you’ve charged on your credit card. Every time you use a credit card, write down how much you have spent and figure out how much you’ll have to pay that month. If you know you won’t be able to pay your balance in full, try to figure out how much you can pay each month and how long it’ll take to pay the balance in full. Pay Off the Card with the Highest Rate If you’ve got unpaid balances on several credit cards, you should first pay down the card that charges. | EUROPEAN CENTRAL BANK RISK MANAGEMENT FOR CENTRAL BANK FOREIGN RESERVES RISK MANAGEMENT FOR CENTRAL BANK FOREIGN RESERVES EUROPEAN CENTRAL BANK RISK MANAGEMENT FOR CENTRAL BANK FOREIGN RESERVES EDITORS CARLOS BERNADELL PIERRE CARDON JOACHIM COCHE FRANCIS X. DIEBOLD AND SIMONE MANGANELLI Published by European Central Bank May 2004 Address Kaiserstrasse 29 60311 Frankfurt am Main Germany Postal address Postfach 16 03 19 60066 Frankfurt am Main Germany Telephone 49 69 1344 0 Internet http Fax 49 69 1344 6000 Telex 411 144 ecb d This publication is also available as an e-book to be downloaded from the ECB s website. The views expressed in this publication do not necessarily reflect those of the European Central Bank. No responsibility for them should be attributed to the ECB or to any of the other institutions with which the authors are affiliated. All rights reserved by the authors. Editors Carlos Bernadell ECB Pierre Cardon BIS Joachim Coche ECB Francis X. Diebold University of Pennsylvania and Simone Manganelli ECB Typeset and printed by Kern Birner GmbH Co. ISBN 92-9181-497-0 print ISBN 92-9181-498-9 online

• Ngân hàng - Tín dụng
• Metastatic Pancreatic Cancer
• Pancreatic Cancer
• Clinical Course
• Nutrition in Healthy Children
• Growth and Development
• Pediatric Cardiology
• BMC Cancer
• Enzyme gamma glutamyltransferase
• Serum gamma glutamyltransferase
• Overall survival
• Recurrent pancreatic ductal adenocarcinoma
• Recurrent pancreatic cancer
• Gemcitabine nab paclitaxel
• Combination chemotherapy
• Liver metastases
• Liver directed therapy
• Systemic chemotherapy
• Metastatic pancreatic ductal adenocarcinoma
• Nab paclitaxel
• Pancreatic adenocarcinoma
• Randomized phase III trial
• Progressive disease
• Subgroup analysis
• MPACT trial
• Subsequent therapy
• Weekly nab paclitaxel plus gemcitabine
• Phase II study
• H 1 parvovirus
• Oncolytic virotherapy
• Pancreatic ductal adenocarcinoma
• Clinical protocol
• Body mass index
• Prognostic factors
• Physical activity
• Skeletal muscle density
• Metastatic pancreatic adenocarcinoma
• Prognostic factor
• Journal of Biology
• CRISPR/dCas9 activation
• Pancreas cancer
• Pancreatic ductal adenocarcinoma (PDAC)
• Metastatic pancreatic cancer cells
• Real life
• First line chemotherapy
• Locally advanced
• Metastatic disease
• Locally advanced pancreatic adenocarcinoma
• Kaplan–Meier method
• Second line chemotherapy
• Venous thromboembolism
• Predictive value
• Khorana score
• Gemcitabine chemotherapy
• Therapeutics strategy
• Laboratory parameters
• Clinicopathological factors
• White blood cell
• Survival
• Endoscopic Management
• Palliative Therapy